Other potent and selective menin–MLL inhibitors, JNJ-75276617 and SNDX-5613 (VTP-50469), have entered Phase 1 and Phase I/II clinical trials, respectively, for relapsed/refractory acute leukemia. Here, KMT2A is linked to acute leukemia.